A case of Vagococcus fluvialis isolated from the bile of a patient with calculous cholecystitis.
Bacterial identification
Chronic cholecystitis
Gallbladder stones
Vagococcus fluvialis
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
16 Oct 2023
16 Oct 2023
Historique:
received:
25
04
2023
accepted:
11
10
2023
medline:
2
11
2023
pubmed:
17
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Chronic cholecystitis, characterized by persistent inflammation of the gallbladder, predominantly stems from the prolonged presence of gallstones. Calculous cholecystitis has demonstrated a consistent escalation in its incidence over time.Gallbladder stones have been recognized as a predisposing factor for the development of biliary tract infections.Concomitantly, there have been substantial shifts in the distribution and resistance profiles of pathogenic microorganisms responsible for biliary tract infections. The timely acquisition of bile samples for pathogen analysis is of paramount importance, given its critical role in guiding judicious clinical pharmacotherapy and enhancing patient prognosis. We present a case involving a 66-year-old female patient who had previously undergone subtotal gastrectomy due to diffuse large B-cell lymphoma. The patient was admitted to our institution with complaints of abdominal pain. Subsequent diagnostic evaluation revealed concurrent choledocholithiasis and cholecystolithiasis. The patient underwent surgical cholecystectomy as the therapeutic approach. Histopathological examination of the excised gallbladder disclosed characteristic features indicative of chronic cholecystitis. Subsequent laboratory analysis of the patient's bile specimen yielded Gram-positive cocci, subsequently identified through biochemical assays, mass spectrometry, and 16 S rRNA analysis as Vagococcus fluvialis. Further in vitro antimicrobial susceptibility testing using disk diffusion and microfluidic dilution showed that this strain exhibited inhibition zone diameters ranging from 12.0 to 32.0 mm in response to 26 antibiotics, including ampicillin, cefazolin, cefuroxime, cefotaxime, ceftriaxone, cefepime, ampicillin/sulbactam, piperacillin, ciprofloxacin, cefoperazone/sulbactam, imipenem, meropenem, piperacillin/tazobarb, penicillin, erythromycin, chloramphenicol, vancomycin, methotrexate/sulfamethoxazole, teicoplanin, linezolid, tigecycline, cefoxitin, ceftazidime, levofloxacin, minocycline and tobramycin. However, the inhibition zone diameters were 6.0 mm for amikacin, oxacillin, clindamycin, and tetracycline. The patient received ceftazidime anti-infective therapy both preoperatively and within 24 h postoperatively and was discharged successfully one week after surgery. In this study, we present the inaugural isolation and identification of Vagococcus fluvialis from bile specimens of patients afflicted with calculous cholecystitis. This novel finding lays a substantial experimental groundwork for guiding clinically rational antimicrobial therapy and advancing the exploration of relevant pathogenic mechanisms pertaining to Vagococcus fluvialis infections.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic cholecystitis, characterized by persistent inflammation of the gallbladder, predominantly stems from the prolonged presence of gallstones. Calculous cholecystitis has demonstrated a consistent escalation in its incidence over time.Gallbladder stones have been recognized as a predisposing factor for the development of biliary tract infections.Concomitantly, there have been substantial shifts in the distribution and resistance profiles of pathogenic microorganisms responsible for biliary tract infections. The timely acquisition of bile samples for pathogen analysis is of paramount importance, given its critical role in guiding judicious clinical pharmacotherapy and enhancing patient prognosis.
CASE PRESENTATION
METHODS
We present a case involving a 66-year-old female patient who had previously undergone subtotal gastrectomy due to diffuse large B-cell lymphoma. The patient was admitted to our institution with complaints of abdominal pain. Subsequent diagnostic evaluation revealed concurrent choledocholithiasis and cholecystolithiasis. The patient underwent surgical cholecystectomy as the therapeutic approach. Histopathological examination of the excised gallbladder disclosed characteristic features indicative of chronic cholecystitis. Subsequent laboratory analysis of the patient's bile specimen yielded Gram-positive cocci, subsequently identified through biochemical assays, mass spectrometry, and 16 S rRNA analysis as Vagococcus fluvialis. Further in vitro antimicrobial susceptibility testing using disk diffusion and microfluidic dilution showed that this strain exhibited inhibition zone diameters ranging from 12.0 to 32.0 mm in response to 26 antibiotics, including ampicillin, cefazolin, cefuroxime, cefotaxime, ceftriaxone, cefepime, ampicillin/sulbactam, piperacillin, ciprofloxacin, cefoperazone/sulbactam, imipenem, meropenem, piperacillin/tazobarb, penicillin, erythromycin, chloramphenicol, vancomycin, methotrexate/sulfamethoxazole, teicoplanin, linezolid, tigecycline, cefoxitin, ceftazidime, levofloxacin, minocycline and tobramycin. However, the inhibition zone diameters were 6.0 mm for amikacin, oxacillin, clindamycin, and tetracycline. The patient received ceftazidime anti-infective therapy both preoperatively and within 24 h postoperatively and was discharged successfully one week after surgery.
CONCLUSION
CONCLUSIONS
In this study, we present the inaugural isolation and identification of Vagococcus fluvialis from bile specimens of patients afflicted with calculous cholecystitis. This novel finding lays a substantial experimental groundwork for guiding clinically rational antimicrobial therapy and advancing the exploration of relevant pathogenic mechanisms pertaining to Vagococcus fluvialis infections.
Identifiants
pubmed: 37845605
doi: 10.1186/s12879-023-08696-w
pii: 10.1186/s12879-023-08696-w
pmc: PMC10578025
doi:
Substances chimiques
Ceftazidime
9M416Z9QNR
Sulbactam
S4TF6I2330
Anti-Bacterial Agents
0
Anti-Infective Agents
0
Ampicillin
7C782967RD
Piperacillin
X00B0D5O0E
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
689Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Enferm Infecc Microbiol Clin (Engl Ed). 2021 Aug-Sep;39(7):335-339
pubmed: 34353510
J Gastroenterol Hepatol. 2020 Jan;35(1):56-64
pubmed: 31359494
G3 (Bethesda). 2021 Jan 18;11(1):
pubmed: 33561240
J Vector Borne Dis. 2015 Mar;52(1):52-7
pubmed: 25815867
Int J Syst Evol Microbiol. 2019 Aug;69(8):2268-2276
pubmed: 31125302
Biomed Environ Sci. 2021 Oct 20;34(10):834-837
pubmed: 34782051
Int J Syst Evol Microbiol. 2020 Apr;70(4):2493-2498
pubmed: 32195646
J Microbiol. 2021 Feb;59(2):132-141
pubmed: 33355892
Int J Syst Bacteriol. 1999 Jul;49 Pt 3:1251-4
pubmed: 10425788
Syst Appl Microbiol. 2018 Mar;41(2):65-72
pubmed: 29306597
J Clin Microbiol. 1997 Nov;35(11):2778-81
pubmed: 9350732
J Infect Chemother. 2021 Feb;27(2):359-363
pubmed: 33036895
J Infect Dev Ctries. 2020 Nov 30;14(11):1314-1319
pubmed: 33296345
BMC Genomics. 2022 Aug 25;23(1):618
pubmed: 36008774
J Hepatobiliary Pancreat Surg. 2007;14(1):15-26
pubmed: 17252293
J Cardiol Cases. 2019 Jul 26;20(4):129-131
pubmed: 31969941
Microbiol Spectr. 2022 Aug 31;10(4):e0095422
pubmed: 35730941
Curr Microbiol. 2008 Sep;57(3):235-8
pubmed: 18560938
J Appl Bacteriol. 1989 Oct;67(4):453-60
pubmed: 2479630